Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

Power point presentation on CTIX web page.

http://cellceutix.com/wp-content/uploads/2014/06/QIDP_21May2015-Power-Point-Presentation.pdf

Recounts Brilacidin information previously released.

Gram negative drug has the potential to be another big winner,CC-1807

New information regarding the gram negative drug: CC-1807 being optimized for urinary tract infections, bacteremia and lung infections {pneumonia}

Optimized for expanded Gram neg coverage to include Pseudomonas and Acineobacter

From power point:

Gram-negative activity evident in several structural series of small nonpeptidic mimetics of host defense proteins

2 series show low cytotoxicity, favorable PK properties and robust efficacyin vitro and in vivo against Enterobacteriaceae organisms

CC-1807 is potently active against clinical isolates of E. coli, K. pneumoniae and E. cloacae, including MDR CRE strains

Additional preclinical efficacy studies with CC-1807 are in progress

Dose optimization in lung infection models UTI and bacteremia

Chemical optimization of CC-1807 and additional analogs is continuing
Expand coverage to Pseudomonas and Acinetobacter spp